We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

BioAtla Inc (BCAB) USD0.0001

Sell:$22.50 Buy:$22.54 Change: $0.49 (2.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.49 (2.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
Change: $0.49 (2.13%)
Market closed |  Prices as at close on 3 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

BioAtla, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. Its product candidate includes BA3011, BA3021, BA3071. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL. its second product candidate, BA3021, which is a CAB ADC targeting ROR2. Its third product candidate, BA3071, is a CAB anti-CTLA-4 antibody. The Company also uses its CAB technology to develop bispecific antibodies, which bind both a tumor-specific antigen and a T cell receptor using CAB antigen-binding domains. Its bispecific product candidate includes BA3182, BA3142, EGFR and Nectin-4.

Contact details

11085 Torreyana Road
United States
+1 (858) 5580708

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
Market cap:
$803.02 million
Shares in issue:
38.33 million
United States
US dollar

Key personnel

  • Jay Short
    Chairman of the Board, Chief Executive Officer, Co-Founder
  • Scott Smith
    President, Director
  • Richard Waldron
    Chief Financial Officer, Senior Vice President
  • Christian Vasquez
    Vice President - Finance, Corporate Controller, Company Secretary
  • Eric Sievers
    Chief Medical Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.


The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.